Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019

Date: February 1, 2011
Pages: 308
Price:
US$ 2,950.00
License [?]:
Publisher: MedMarket Diligence, LLC
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery
ID: P738F029D68EN
Leaflet:

Download PDF Leaflet

Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019
This report is a detailed market and technology assessment and forecast of the products and technologies in the clinical management of obesity (bariatrics). The report describes the current and projected patient population in obesity, detailing their incidence worldwide, with available incidence by country for the U.S., major European countries, major countries in Asia/Pacific (including Japan, China, India and Australia), the clinical practices in their management to encompass surgical approaches, medical supervised severely restricted diets, drug therapies, OTC treatments, biopharmaceuticals, non-pharmacologic approaches and weight maintenance approaches. The report describes clinical trends in the management of the obese. The report details the products on the market and the status of those in development for bariatric surgery, drug therapy, gastric stimulation devices, brain stimulation devices, combination therapies and genetic therapy and other therapies under development, and will provide current and worldwide market forecasts (2009-2019) separately for pharmaceuticals (with separate segment forecast data for satiety, malabsorption, appetite suppression and combination drugs) and devices (with separate segment forecast data for stomach restriction artificial fullness, malabsorption, gastric emptying and appetite suppression), with current (2009) market shares of the leading competitors in each segment. The report addresses the challenges to obesity drug approval and the realistic prospects for obesity drugs and their changing opportunities to succeed in the U.S. and international markets. The report profiles the 45 leading competitors, detailing current and potential position in the market, their products and their market strengths and likelihood of future success.
EXECUTIVE SUMMARY

SECTION 1: CLINICAL BACKGROUND OF OBESITY

1.1 Clinical Diagnosis of Obesity
  1.1.1 Body Mass Index Scale
  1.1.2 Measuring BMI vs. Measuring Adiposity
  1.1.3 Classification of Obesity
  1.1.4 Overweight, Obesity, Morbid Obesity, Super Obesity
  1.1.5 Genetic Testing for Obesity
1.2 Obesogenic Influences
  1.2.1 Dietary Changes Over the Last Twenty Years
  1.2.2 Sedentary Lifestyles
  1.2.3 Ongoing Research into Causes
1.3 Metabolic Pathways of Energy Homeostasis
  1.3.1 Role of the Hypothalamus
  1.3.2 Role of the Stomach
  1.3.3 Role of the Small Intestine
  1.3.4 Role of the Pancreas
  1.3.5 Role of Adipose Tissue, An Endocrine Organ
  1.3.6 Other Peptides
  1.3.7 Obesity as Survival Mechanism
1.4 Co-Morbidities of Overweight and Obesity
  1.4.1 Metabolic Syndrome
  1.4.2 Effects of Obesity on Immune Function
  1.4.3 Racial Differences in Co-morbidities
  1.4.4 Type 2 Diabetes and Insulin Resistance
  1.4.5 Hypertension
  1.4.6 Dyslipidemia
  1.4.7 Depression
  1.4.8 Osteoarthritis
  1.4.9 Asthma
  1.4.10 Sleep apnea
  1.4.11 Obesity and Cancer
1.5 Global Incidence and Prevalence of Obesity
  1.5.1 By Geographic Region
    1.5.1.1 USA, Canada, Mexico, Brazil
    1.5.1.2 European Union
    1.5.1.3 Asia-Pacific
  1.5.2 By Age Group
    1.5.2.1 Incidence and Prevalence among Children
    1.5.2.2 Incidence and Prevalence among Elderly
  1.5.3 Incidence and Prevalence of Morbid Obesity

SECTION 2: THE IMPACT OF OBESITY

2.1 Costs Related to Treating Obesity and Co-Morbidities
  2.1.1 Current Healthcare Expenses
    2.1.1.1 Spending in the USA
    2.1.1.2 Outside of the U.S., Spending Also Rising
  2.1.2 The Looming Wave of Type 2 Diabetes
2.2 Impact on Businesses
  2.2.1 Increased Health and Life Insurance Costs
  2.2.2 Increased Costs Shouldered by Employers
  2.2.3 Debate: Pay Employees to Lose Weight?
2.3 Legislating Prevention and Weight Loss
  2.3.1 Healthcare Reform and Obesity
  2.3.2 Changing Society
  2.3.3 Pressure on the Food Industry

SECTION 3: CLINICAL APPROACHES TO THE TREATMENT OF OVERWEIGHT AND OBESITY

3.1 Role of Behavior Modification and Lifestyle Changes
  3.1.1 Behavior Modification with Pharmacotherapies
  3.1.2 Specialists’ Use of Pharmaceuticals
  3.1.3 Medically Supervised Low Calorie and Very Low Calorie Diets (LCDs and VLCDs)
  3.1.4 Why Diets Usually Fail
  3.1.5 The Diogenes Study’s Dietary Recommendations
3.2 Non Prescription Weight Loss Products
3.3 Pharmaceutical Treatment of Obesity: Past, Present and Future Drugs
  3.3.1 The US FDA’s Guidance for Industry Developing Products for Weight Management
  3.3.2 Definition of Satiety vs. Appetite Suppression
  3.3.3 Definition of Combination Drugs
  3.3.4 The Bloom is Off the Rose: Promising Drugs Which Have Failed, and Why
    3.3.4.1 Phentermine/Fenfluramine Combination
    3.3.4.2 Abbott’s Meridia (Sibutramine)
    3.3.4.3 Vivus’ Qnexa: Out for Good?
    3.3.4.4 Arena’s Lorqess: Not out of the picture yet
  3.3.5 Prescription Drugs Currently on the Market
    3.3.5.1 Appetite Suppression Drugs
    3.3.5.2 Malabsorption Drugs
    3.3.5.3 Satiety Drugs
    3.3.5.4 Combination Drugs
  3.3.6 Areas of Pharmaceutical Research
    3.3.6.1 Melanocortin Receptor System
    3.3.6.2 Cannabinoid Receptor Antagonists
    3.3.6.3 GLP-1 Analogs
    3.3.6.4 Methionine Aminopeptidase 2 (MetAP2) Inhibitor
    3.3.6.5 Appetite Suppression Drugs
    3.3.6.6 Malabsorption Drugs
    3.3.6.7 Satiety Drugs
    3.3.6.8 Combination Drugs
  3.3.7 Safety: The Major Diet Drug Hurdle
3.4 Non- Pharmaceutical Options for Treating Obesity
  3.4.1 Metabolic/Bariatric Surgery
    3.4.1.1 Buchwald and Oien Research, 2009
    3.4.1.2 Vertical Banded Gastroplasty
    3.4.1.3 Roux-en-Y Surgery
    3.4.1.4 Sleeve Gastrectomy
    3.4.1.5 Biliopancreatic Diversion with Duodenal Switch
    3.4.1.6 Jejuno-ileal Bypass: An Obsolete Procedure
  3.4.2 Devices to Treat Obesity
    3.4.2.1 Restrictive Devices
    3.4.2.2 Artificial Fullness Devices
    3.4.2.3 Malabsorption Devices
    3.4.2.4 Devices to Control Gastric Emptying
    3.4.2.5 Appetite Suppressive Devices
    3.4.2.6 Gastric Electrical Stimulation

SECTION 4: MARKET ASSESSMENT

4.1 Recent Developments Impacting Market Forecasts
4.2 Anticipated Developments Underlying the Market Forecast
4.3 Global Market for Obesity Treatments
  4.3.1 Pharmaceuticals
    4.3.1.1 Pharmaceutical Treatments for Obesity Entering the Market During the Forecast Period (2011-2019)
  4.3.2 Devices
    4.3.2.1 Medical Device Treatments for Obesity Entering the Market During the Forecast Period (2011-2019)
4.4 Market Shares of Leading Companies
  4.4.1 Leading Pharmaceutical Companies
  4.4.2 Leading Device Companies
4.5 Americas Market for the Treatment of Obesity
  4.5.1 USA
  4.5.2 Canada
  4.5.3 Mexico
  4.5.4 Brazil
4.6 European Market for the Treatment of Obesity
  4.6.1 United Kingdom
  4.6.2 Germany
  4.6.3 France
  4.6.4 Spain
  4.6.5 Italy
  4.6.6 Rest of Europe
4.7 Asia-Pacific Markets for the Treatment of Obesity
  4.7.1 Japan
  4.7.2 China
  4.7.3 India
  4.7.4 Australia
4.8 ROW Markets for the Treatment of Obesity
4.9 Strategies in the Global Obesity Market
  4.9.1 Market Drivers
    4.9.1.1 Significant Unmet Needs
    4.9.1.2 The Need for a Variety of Treatment Options
    4.9.1.3 Device Opportunity Grows Due to Lack of Drugs
    4.9.1.4 Healthcare Reform
    4.9.1.5 Treating Obesity to Avoid Costly Co-Morbidities
  4.9.2 Market Restraints
    4.9.2.1 Intense Complexity of the Metabolic Regulatory System
    4.9.2.2 Time, Costs, Risks Involved in Developing a More Efficacious Drug
    4.9.2.3 Tightening of Safety Requirements for Obesity Drugs
    4.9.2.4 Data Showing Lack of Sustainable Weight Loss with Gastric Banding
    4.9.2.5 Lack of Reimbursement
  4.9.3 Strategies for Market Success

SECTION 5: COMPANY PROFILES

5.1 7TM Pharma
5.2 Abbott Laboratories
5.3 Allergan
5.4 Amylin Pharmaceuticals
5.5 Arena Pharmaceuticals
5.6 AstraZeneca
5.7 BAROnova Therapeutics
5.8 BaroSense
5.9 BFKW, LLC (c/o Legacy Capital Advisors, LLC)
5.10 Covidien
5.11 CR Bard, Inc.
5.12 Crospon, Inc.
5.13 Eli Lilly & Company
5.14 EndoGastric Solutions
5.15 EndoSphere
5.16 EnteroMedics, Inc.
5.17 Ethicon Endo-Surgery, Inc. (JNJ)
5.18 Gelesis, Inc.
5.19 GI Dynamics
5.20 GlaxoSmithKline
5.21 Helioscopie
5.22 Interleukin Genetics
5.23 IntraPace
5.24 Laboratoire Endalis
5.25 Longevity Surgical, Inc.
5.26 Merck
5.27 MetaCure
5.28 Nestlé Healthcare Nutrition
5.29 NeuroSearch A/S
5.30 Novo Nordisk
5.31 Orexigen Therapeutics, Inc.
5.32 Pfizer, Inc.
5.33 ReShape Medical
5.34 Rhythm Pharmaceuticals
5.35 SafeStitch Medical, Inc.
5.36 Sanofi-Aventis
5.37 Satiety, Inc.
5.38 Scientific Intake, LLC
5.39 Shionogi & Co., Ltd.
5.40 Silhouette Medical, Inc.
5.41 Spatz FGIA, Inc.
5.42 Surface Logix, Inc.
5.43 USGI Medical
5.44 ValenTx, Inc.
5.45 Verva Pharmaceuticals Ltd.
5.46 Vivus, Inc.
5.47 Zafgen, Inc.

SECTION 6: CLINICAL TRIALS

APPENDIX: COMPANY DIRECTORY
List of Exhibits
Exhibit ES-1: Estimated Overweight & Obesity (BMI > 25 kg/m2) Prevalence, Males, Aged 15+, 2010
Exhibit ES-2: Past and Projected Future Overweight Rates in Selected O.E.C.D. Countries
Exhibit ES-3: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
Exhibit ES-4: Regional Percent Revenue Shares, 2009
Exhibit ES-5: Manufacturer Percent Revenue Shares, Global Obesity Market, 2009
Exhibit 1-1: Calculation of Body Mass Index (BMI)
Exhibit 1-2: Proposed WHO Classification of BMI in Adult Asians
Exhibit 1-3: The International BMI Classification of Adult Underweight, Overweight and Obesity According to the World Health Organization (WHO)
Exhibit 1-4: The Human Gastrointestinal Tract
Exhibit 1-5: From Chronic Energy Imbalance to Co-Morbidities
Exhibit 1-6: Relative Risk of Mortality by BMI in US Men
Exhibit 1-7: Relative Risk of Mortality by BMI in US Women
Exhibit 1-8: World Incidence and Prevalence for Cancers Associated with Obesity
Exhibit 1-9: AICR Estimated Cases Per Year of Cancers Linked to Excss Body Fat
Exhibit 1-10: Populations and Rates of Obesity of Selected Countries, 2009
Exhibit 1-11: Estimated Overweight & Obesity (BMI > 25 kg/m2) Prevalence, Males, Aged 15+, 2010
Exhibit 1-12: Past and Projected Future Overweight Rates in Selected O.E.C.D. Countries
Exhibit 1-13: Percent of Adults Who are Overweight/Obese, by Country, 2010
Exhibit 1-14: USA Obesity Prevalence by State, 2004.
Exhibit 1-15: USA Obesity Prevalence by State, 2009.
Exhibit 1-16: Prevalence of Obesity in Canada for 1978-2005 (Measured Values)
Exhibit 1-17: Prevalence of Overweight and Obesity in Women and Men in Mexico from a Nationally Representative Sample and a Sample of Low-Income Rural Mexicans
Exhibit 1-18: WHO Prevalence of Obesity by Sex, Adults Aged 15 and Over, Latest Available Year, Europe
Exhibit 1-19: States of India ranked by percentage of overweight or obese (2006)
Exhibit 1-20: Percent of Children in Select Age Groups and Countries Who are Overweight (Including Obese), 2010
Exhibit 3-1: FDA List of Tainted Weight Loss Products, March 2009
Exhibit 3-2: Companies with Obesity Pharmaceuticals on Market or in Development, 2010
Exhibit 3-3: Number Of Bariatric Surgeons and Bariatric Surgery Operations, 2008
Exhibit 3-4: Global Trend in Metabolic/Bariatric Surgery, 2003-2013
Exhibit 3-5: Global Trends in Metabolic/Bariatric Surgery, 2003-2013
Exhibit 3-6: Regional Trend in Metabolic/Bariatric Surgery, USA/Canada, 2003-2008
Exhibit 3-7: USA/Canada Trends in Metabolic/Bariatric Surgery, 2003-2013
Exhibit 3-8: Regional Trends in Metabolic/Bariatric Surgery, Europe, 2003-2013
Exhibit 3-9: European Trends in Metabolic/Bariatric Surgery, 2003-2013
Exhibit 3-10: Regional Trends in Metabolic/Bariatric Surgery, Asia/Pacific, 2003-2013
Exhibit 3-11: Regional Trends in Metabolic/Bariatric Surgery, Asia/Pacific, 2003-2013
Exhibit 3-12: Regional Trend in Metabolic/Bariatric Surgery, Rest of World, 2003-2013
Exhibit 3-13: Regional Trends in Metabolic/Bariatric Surgery, Rest of World, 2003-2013
Exhibit 3-14: Companies with Obesity Devices on Market or in Development, 2010
Exhibit 4-1: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
Exhibit 4-2: Global Market for Treatment of Obesity, 2009-2019 (USD millions)
Exhibit 4-3: Total Modality Market Shares by Percent Revenues, 2009
Exhibit 4-4: Total Modality Market Shares by Percent Revenue, 2019
Exhibit 4-5: Global Markets for Pharmaceutical Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-6: Global Markets for Pharmaceutical Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-7: Global Market for Device Treatment of Obesity, 2009-2019, (USD Millions)
Exhibit 4-8: Global Market for Medical Device Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-9: Percent Revenue Shares, Global Obesity Market, 2009
Exhibit 4-10: Percent Revenue Shares, Global Anti-Obesity Drug Market, 2009
Exhibit 4-11: Percent Revenue Shares, Global (Off-Label) Satiety Drug Market, 2009
Exhibit 4-12: Percent Revenue Shares, Global Pharmaceutical Appetite Suppression Market, 2009
Exhibit 4-13: Percent Revenue Shares, Global Anti-Obesity Devices Market, 2009
Exhibit 4-14: Percent Revenue Shares, Global Restrictive Devices Market, 2009
Exhibit 4-15: Percent Revenue Shares, Global Artificial Fullness Devices Market, 2009
Exhibit 4-16: Percent Revenue Shares, Global Appetite Suppression Devices Market, 2009
Exhibit 4-17: Americas Market for Treatment of Obesity, 2009-2019
Exhibit 4-18: Americas Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-19: USA Market for Treatments of Obesity, 2009-2019 (USD Millions)
Exhibit 4-20: Canada Market for Treatments of Obesity, 2009-2019 (USD Millions)
Exhibit 4-21: Mexico Market for Treatments of Obesity, 2009-2019 (USD Millions)
Exhibit 4-22: Brazil Market for Treatments of Obesity, 2009-2019 (USD Millions)
Exhibit 4-23: European Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-24: EU Obesity Percent Revenue Market Shares by Country, 2009
Exhibit 4-25: EU Obesity Percent Revenue Market Shares by Country, 2019
Exhibit 4-26: European Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-27: UK Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-28: Trends in Gastric Bypass vs. Gastric Banding, England, 2000-2007
Exhibit 4-29: Germany Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-30: France Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-31: Spain Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-32: Italy Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-33: Rest of Europe Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-34: Asia-Pacific Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-35: Asia-Pacific Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-36: Japan Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-37: China Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-38: India Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-39: Australia Market for Treatment of Obesity, 2009-2019 (USD Millions)
Exhibit 4-40: Rest of World Market for Treatment of Obesity, 2009-2019 (USD Millions)
Skip to top


Ask Your Question

Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: